Abstract The senile plaques of Alzheimer's disease contain a high concentration of beta-amyloid (bA) protein, which may affect the glial population in the septal nucleus, an area of increased risk in AD. bA toxicity was measured in septal glia, via a dose-response experiment, by quantifying the effects of three different doses (0.1, 1, and 10 lM) of bA on cell survival. Astrocytes from embryonic day-16 rats were grown in serum-free media in a single layer culture. Cells were treated on day in vitro (DIV)1 and survival was determined on DIV3 to ascertain which concentration was most toxic. In a separate set of experiments, an attempt was made to protect glial cells from the degenerative effects of bA, with treatments of growth factors and estrogen. bA (10 lM) treatment was administered on DIV1, on DIV2 the cells were treated with estrogen (EST, 10 nM), insulin-like growth factors (IGF1 and IGF2, each 10 ng/ml), basic fibroblast growth factor (bFGF, 5 ng/ml) or nerve growth factor (NGF, 100 ng/ml), and on DIV3 the cells were visualized and quantified by fluorescence microscopy with DAPI (4,6-diamidino-2-phenylindole). In addition to dose-response and glial protection, experiments were also conducted to determine whether toxic effects were due to apoptosis. Our results suggest that the survival of glial populations is significantly affected in all three concentrations (0.1, 1.0, and 10 lM) of bA. Glial protection was evident in the presence of NGF, for it showed the significantly highest survival rate relative to the bA treatment alone. Furthermore, toxic effects of bA appear to be due primarily to apoptosis. Significant reversal of bA-induced apoptosis was seen with bFGF and IGF1.
Introduction
Alzheimer's disease (AD) is an age-related, neurodegenerative disease that results in memory loss, behavior and personality changes, as well as a decrease in thinking abilities; physical manifestations include amyloid plaques, neurofibrillary tangles, and dendritic atrophy as well as neurotransmitter deficits in specific parts of the brain [1] . These effects are thought to be due to breakdown of the connections between nerve cells and formation of betaamyloid (bA) protein plaques in specific regions of the brain including the septal nucleus [2, 3] . The plaques that characterize AD contain bA, a protein which is toxic to a number of neuronal populations [1] . It is made by proteolytic cleavage of the amyloid precursor protein (bAPP) which appears to function in neuronal adhesion, synaptogenesis, and neurite outgrowth [1] . Amyloid precursor protein is secreted by neurons, astrocytes, and microglia in the human brain [4] . The beta 25-35 region is a toxic fragment that has been isolated from the larger protein [5] .
Amyloid plaques appear early during Alzheimer's disease and their development is intimately linked to activated astrocytes and microglia [6] . Alzheimer's disease is marked by apoptosis of astrocytes [7, 8] . Astrocytes are capable of accumulating substantial amounts of neuron-derived, bA material and other neuron-specific proteins as a consequence of their debris-clearing role in response to local neurodegeneration [9] . Since astrocytes provide physical support for neurons, some of the chemicals needed for proper functioning of neurons, and help control the chemical composition of fluid surrounding neurons [10, 11] , it is likely that a number of effects may be indirectly mediated via glial cells. This is a possibility because glial cells have receptors for, and are responsive to, a number of growth factors [12, 13] and astroglial progenitor cells are responsive to bFGF [14] . These cells both secrete NGF and are responsive to NGF [15] . Microglial secretion of NGF in response to bA may provide one mechanism of cellular regeneration [16] . The purposes of this study were [1] to assess dose dependent effects of bA in astrocyte glia cells cultured from embryonic rat brain, [2] to determine whether subsequent treatment with growth factors could reverse bA toxicity, and [3] to determine whether toxic effects might be due to apoptosis and reversible with subsequent growth factor treatment.
Materials and methods

Dissection and cell culture
Glial plane
Glial cultures were prepared from embryonic day 16 (E16) Sprague-Dawley rat cortex (Charles River, Wilmington, MA). Cortices were dissected and minced in a sterile environment in calcium and magnesium-free Hank's balanced salt solution (HBSS) at 20°C. Tissue was digested with trypsin (Sigma, St. Louis, MO, 20 min at 37°C, 0.1%), followed by DNAse (Sigma, 5 min at 37°C, 0.3 mg/ml with 0.5 mg/ml MgSO 4 ). Cells were mechanically separated by passage through a Pasteur pipette and the suspension was centrifuged at 1000 · g for 5 min. Cells were resuspended in 10% horse serum (Hyclone, Logan, UT) in Dulbecco's modified Eagle Medium (DMEM, Hyclone), plated onto uncoated 60 mm tissue culture dishes (Corning, Corning, NY) and transferred to silane treated Poly-L-Lysine coated glass coverslips before treatment [17] . The day before the treatment the media in the plates containing the glial cells was replaced with 1 ml of N2.1 medium (DMEM supplemented with 20 nM progesterone (Sigma), 100 nM putrescine (Sigma), 30 nM selenium dioxide (Sigma), 5 lg/ ml insulin (GIBCO), 100 lg/ml transferrin (BoehringerMannheim), 55 lg/ml pyruvate (Sigma), 500 lg/ml bovine albumin (Sigma), and 2 mM-glutamine (GIBCO).
Treatment of experimental groups
Dose response
Cells were treated on days in vitro (DIV) 1 with three concentrations of bA (25-35 fragment, 0.1, 1, and 10 lM, Biosource Camarillo, CA). Controls were treated with water only. bA was added to sterile-filtered water and allowed to aggregate at 4°C. On DIV2 the cells received no treatment and on DIV3 survival was visualized in random fields with 4,6-diamidino-2-phenylindole (DAPI -Sigma St. Louis, MO) under a fluorescence microscope (Olympus BMAX) with a 450 nm excitation [18] . In the case of the control experiments with reverse bA (35-25 Global Peptide, CO), both the preparation and treatment of cells were the same as with the bA.
Immunocytochemistry
Cells on coverslips were fixed with 3% paraformaldehyde/ 0.2% glutaraldehyde in PBS for 10 min at 0.5°C. Cell membranes were permeabilized with 0.1% Triton X-100 in PBS for 20 min at 20°C. Cells were incubated for 1 h at 20°C in 3% bovine serum albumin in PBS to block nonspecific binding. Immunostaining was performed by incubation with anti-glial fibrillary acidic protein (GFAP; 1:100, Sigma) for 1 h at 20°C followed by exposure to a biotinylated-goat anti-mouse IgG (KPL) and avidin horseradish peroxidase (KPL). Cell were developed by exposure to True Blue peroxidase substrate (KPL).
Protection
Cells were treated on DIV 1 with bA (10 lM). On DIV 2 cells were treated with either estrogen (EST, Sigma: 10 nM), IGF1 (10 ng/ml), IGF2 (10 ng/ml), b-FGF (5 ng/ ml), or NGF (100 ng/ml), (all from Upstate Biotechnology Incorporated, Lake Placid, NY). Each of these factors was diluted in DMEM and added to the media with the exception of EST, which was prepared in ethanol at a concentration of 25 mM and subsequently diluted 2.5 · 10 6 times in DMEM. On DIV3 the cells received no treatment and survival was quantified by fluorescence microscopy with DAPI as described previously.
Apoptosis
Cells were treated as for protection experiment described previously. On DIV3 silane-coated glass coverslips with adhered cells were placed in 12-well dishes where the procedures for ApopTagÒ Plus Fluorescein In Situ Apoptosis detection kit were carried out following manufacturer's instructions for determination of apoptosis (Chemicon International Temecula, CA). Upon termination of protocol coverslips were placed on microscope slides and counterstained with 100 uL 46lg/ml propidium iodide (Sigma St. Louis, MO) in HBSS. Cells were visualized under a fluorescence microscope (40·) with 450 nm excitation. Green and red fluorescent cells were counted in randomly selected fields.
Statistical analyses
All slides were assigned to treatment according to a randomized block design, p. 254 in [19] , that is, each slide was assumed to be independent of other slides, then assigned to treatment by lottery. Within a central area in each slide we randomly selected five circular fields (area = 2.54 -mm 2 per field), and within each circular field we counted the number of surviving cells. We used the same method (field and area) to count dead cells. Cells stained red died by necrosis, while cells stained green died by apoptosis. We calculated the proportion of cells dead from apoptosis per field as (number of green cells)/(number of red cells + number of green cells).
SigmaStatÒ 3.0 (2003) was used for all statistical tests, with appropriate interpretation [19, 20] . All tests used the a = .05 level for statistical significance, and we defined P = probability the null hypothesis is true, i.e., the probability that there is no significant pattern present (or no significant cause-effect relationship present). Figure 1A shows a microphotograph of GFAP immunostaining of the cultures; the staining of fibers within the cells indicates their glial origin. Figure 1B shows fluorescence micrographs of cultured embryonic rat astrocytes. Figure 2 shows the mean (±1 S.E.) number of surviving glial cells per field in the bA dose-dependence experiment.
Results
Comparison of means with ANOVA revealed significant differences (F = 5.25, d.f. = 6, 60; P = .003). The HolmSidak post-test method (assuming a = .05) indicated the means for 10.0 bA (t = 3.32), 1.0 bA (t = 3.44), and 0.1 bA (t = 2.83) were all significantly different from the control mean. Figure 3 shows the mean (±1 S.E.) number of surviving glial cells per field in the growth-factor and estrogen experiment. Comparison of means with ANOVA revealed significant differences (F = 3.93, d.f. = 6, 128; P < .001). The Holm-Sidak post-test method (assuming a = .05) indicated only the means for control (t = 3.46) and NGF (t = 3.02) were significantly higher than the mean for the bA only treatment. Figure 4 shows the mean (± 1 S.E.) mean proportion of cells dead by apoptosis per field in the growth-factor and estrogen experiment. Comparison of means with ANOVA revealed significant differences (F = 2.23, d.f. = 6, 135; P = 0.044). The Holm-Sidak post-test method (assuming a = .05) indicated only the means for control (t = 2.97), IGF1 (t = 3.11), and bFGF (t = 2.84) were significantly lower than the mean for the bA only treatment. Figure 5 shows the mean (± 1 S.E.) percent survival (cells/field) in 10 lM concentration treatment for toxic and non-toxic form (reverse bA, 35-25) of beta-amyloid. Comparison of means with ANOVA revealed significant differences (F = 6.256, d.f. = 2, 66; P = 0.003). The Holm-Sidak post-test method (assuming a = .05) indicated only the mean the toxic bA treatment was significantly different from control (t = 3.46; P = 0.001). This demonstrates that effect on survival is due to toxic bA, as control experiments with non-toxic reverse bA had no statistically significant effects (t = 1.379; P = 0.173).
Discussion
Although the specific relationship between the activation of glial cells and neurodegeneration remains uncertain, previous research suggests that bA plays an important role in activating factors in glial cells leading to an inflammatory reaction in the brain [21] . As a result of such inflammation bA toxicity may result in astrocytic apoptosis, a factor which would critically affect the survival of neuronal cells [22] . Thus preventing this glial self-destruction would possibly decrease the toxicity of bA in AD patients. In this experiment an attempt was made to reverse apoptotic cell death via growth factors and estrogen. Our survival results indicate that bA appears to be toxic to glial cells especially at higher concentrations (10 lg/ml = 10 lM). Previous work by other researchers also indicates a decrease of cholinergic neurons in primary septal glia cultures upon treatment with 10 lM bA [23] . A decreased viability in primary rat cortical mixed cultures was also observed with the same concentration of bA [24] .
Survival in control cells after 3 days in culture is 29% (71% cell death) with beta-amyloid decreasing this survival by 73% relative to the control. As apoptosis in the control cells after 3 days in vitro is 29%, and cell death is 71%, the other 42% must be accounted for by necrosis. bA may be toxic via a necrosis mechanism as well. This is further indicated by the effect on survival versus apoptosis. bA decreased survival by 73% but increased apoptosis by only 33%, suggesting that some effect of bA must be due to necrosis. Both apoptosis and necrosis may result from the same insult, and one form of cell death may induce the other [25] . Both apoptotic and necrotic degeneration have been observed in neuronal death in Alzheimer's disease [25] . In this study, survival was quantitated via measurement of fluorescein diacetate uptake and activation by living cells. Apoptosis, as described in this study, was quantitated as a result of DNA fragmentation and chromatin condensation. Uptake of propidium iodide, a molecule which is not generally taken up by living cells, was used as the counterstain for both tests. Nerve growth factor protects the cells against beta-amyloid effects on survival but does not cause a statistically significant effect on apoptosis. Basic fibroblast growth factor and IGF I cause statistically significant decrease in apoptosis without a parallel increase in survival.
In both types of experiments there is the possibility that increasing the number of experiments would increase the number of factors which show statistically significant effects; thus it is possible that NGF increased survival without a concomitant decrease in apoptosis as a result of Fig. 1 (A) The photomicrographs below were taken following immunocytochemistry for GFAP (Methods) at a magnification of 400 · (left) using an Olympus BX60 microscope. Image on the right (1000 ·) shows specific immunostaining of fibers. (B) Fluorescence micrographs of cultured embryonic rat astrocytes incubated with the nuclear stain, DAPI (black scale bar = 100 lm). The cells in the left panel were treated in control without bA. The cells in the right panel were treated with 10 lM bA. Images were taken on DIV3 as described in Materials and Methods 3 Mean number (±1 S.E.) of cells surviving per field (growth factor and estrogen doses: bFGF = 5 ng/ml, NGF = 100 ng/ml, IGF1 and IGF2 = 10 ng/ml, EST = 10 nM); n = number of fields counted per treatment, and * indicates treatment mean significantly greater than mean for bA treatment experimental design. A second theory would be that NGF increased survival by an effect on necrosis without affecting apoptosis. While most data supports the hypothesis that NGF is protective against apoptosis rather than necrosis [26] , there is also evidence that NGF has effects by blocking necrosis [27] . In addition, bFGF and IGF I blocked apoptosis without altering survival. As apoptosis makes up less than half of the cell death in the cultures an effect on necrosis would be likely to hide this effect. In fact, bFGF has been shown to increase necrosis in cortical cells [28] and IGF I appears to aggravate necrosis in cortical neurons [29] , thus the decrease in apoptosis may be negated by an increase in necrosis.
Potential differences with regard to effectiveness of various factors may be the result of differences in intracellular mechanisms of action. Both cultured rat astrocytes as well as human astrocytic cell lines produce, have receptors for, and respond to a variety of growth factors [13] . They are also important for removing the bA which accumulates in them and can lead to astrocytic lysis [9] . Reactive gliosis is a normal response to CNS trauma or neurodegeneration. Thus it is imperative to understand their response to potential treatments [30] . Receptors for NGF are present on glial cells within the cortex [31, 32] . NGF receptors and estrogen receptors are co-expressed in nervous tissue and estrogen can upregulate the NGF highaffinity receptor, trkA [33] . NGF increases survival by preventing apoptosis that occurs in the absence of NGF via p53-induced increases in the apoptotic protein Bax [34] . These results are important since previous research shows that these cells both secrete NGF and are responsive to NGF [15] , thus microglial secretion of NGF in response to bA may provide a mechanism of cellular regeneration [16] . This is significant since recent research shows that NGF is useful in treating AD [35] .
Receptors for IGF I are present on astrocytes from the brain [36] [37] [38] and are increased following injury [38] . In cerebellar cells, IGF I increases the anti-apoptotic proteins Bcl-2 and Bcl-x L and decreases the apoptotic protein Bax, leading to decreased caspase3 activity [39] . IGF I and estrogen receptors are both present in developing and adult brain, frequently in the same cells, and estrogen and IGF I interact at several points in the apoptosis pathway; for instance, only in the presence of the IGF I receptor, does estrogen increase Bcl-2 [40] .
Estrogen targets glial cells in the central nervous system [41, 42] . Estrogen acts by binding to an intracellular receptor which then binds to estrogen-responsive elements on the DNA; in addition estrogen may bind to estrogen receptor-like molecules in the plasma membrane [33] . Like IGF I, estrogen can decrease apoptosis both by an increase in the anti-apoptotic proteins Bcl-2 and Bcl-x L , and by a decrease in the apoptotic protein, BAD, leading eventually to decreased caspase3 activity [33] .
bFGF receptors are present in astrocytes and function in response to CNS injury [43, 44] . They appear to stimulate the bcl-2 gene as well [45] . Other researchers have shown that astrocytes respond to bFGF [12, 14] although we did not see a significant effect for bFGF, IGFI, IGFII, or estrogen in the protection from bA toxicity under the conditions of the survival study.
IGF II and its receptors are present and functional throughout the developing brain [46] , including astrocytes [37, 38] . Thus receptors for all factors studied are thus present and functioning on developing astrocytes. All of the neuroprotective factors studied appear to intersect at a mechanism involving the Bcl and Bax proteins, which act to alter mitochondrial release of cytochrome C and the associated increased levels of calcium ion and activated caspase3. Differential effectiveness with regard to effects on Fig. 4 Mean proportion (±1 S.E.) of cells dead from apoptosis (growth factor and estrogen doses: bFGF = 5 ng/ml, NGF = 100 ng/ ml, IGF1 and IGF2 = 10 ng/ml, EST = 10 nM); n = number of fields counted per treatment, and * indicates treatment mean significantly lower than mean for bA treatment Fig. 5 Mean percent (±1 S.E.) survival (cells/field) in 10 lM concentration for toxic and non-toxic form (reverse bA, 35-25) of beta-amyloid; n = number of fields counted per treatment, and * indicates treatment mean significantly lower than mean for control treatment apoptosis in this study may be associated with the level to which these proteins are affected, an object of a future study.
Glial cells have important protective [47] and supporting functions in the CNS and their loss has been associated with psychiatric disorders [10] . Apoptosis in astrocytes is associated with AD [7] . There are, however, contradictions regarding the function of astrocytes in neural regeneration and repair. Astrocytes appear to be neuroprotective in ischemia, while the glial scar may prevent regeneration [47] . This reactive gliosis is apparent in response to a number of pathological stimuli in the central nervous system [30] . Astrocytes also have a regulatory role in the CNS [11] ; a factor which makes them promising targets for treatment of CNS disorders [48] .
Glial cells may provide a target for therapeutic intervention in response to nerve injury [48] . In this study bA caused a significant increase in apoptosis relative to the control. Previous research showing bA induced apoptosis in astrocyte-like cells supports the argument that astrocytosis is a common feature of amyloid plaques. Such interaction between bA and astrocytes results in a destructive effect on neurons, which may contribute to neurodegeneration in AD [49] . Fortunately, in this study, IGFI and bFGF protected against these effects on apoptosis. Other factors tested showed a trend toward protection which was not statistically significant.
Although this study was performed on fetal astrocytes, it has implications for mature cells. Multipotent neural precursor cells have been identified in regions of adult mammalian brain including the septum [50] . This, combined with evidence that these cells from non-neurogenic regions may be stimulated to differentiate [50] makes the study of growth factor interactions within the CNS all the more significant. Continuing work in the laboratory includes study of interactions of the same factors in cultured septal neurons.
